I-Mab (IMAB)

NASDAQ: IMAB · IEX Real-Time Price · USD
1.840
-0.020 (-1.08%)
At close: Jun 14, 2024, 4:00 PM
1.820
-0.020 (-1.09%)
After-hours: Jun 14, 2024, 6:58 PM EDT
-1.08%
Market Cap 141.72M
Revenue (ttm) 3.90M
Net Income (ttm) -206.73M
Shares Out 77.02M
EPS (ttm) -2.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 98,306
Open 1.850
Previous Close 1.860
Day's Range 1.830 - 1.860
52-Week Range 1.160 - 3.255
Beta 1.08
Analysts Strong Buy
Price Target 12.25 (+565.76%)
Earnings Date Jun 25, 2024

About IMAB

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 17, 2020
Employees 220
Stock Exchange NASDAQ
Ticker Symbol IMAB
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for IMAB stock is "Strong Buy." The 12-month stock price forecast is $12.25, which is an increase of 565.76% from the latest price.

Price Target
$12.25
(565.76% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastri...

Other symbols: BMY
9 days ago - PRNewsWire

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of hi...

22 days ago - GlobeNewsWire

I-Mab to Participate at the Jefferies Global Healthcare Conference

ROCKVILLE, Md. , May 22, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated...

23 days ago - PRNewsWire

I-MAB Filed 2023 Annual Report on Form 20-F

ROCKVILLE, Md. , April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of hi...

6 weeks ago - PRNewsWire

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

ROCKVILLE, Md. , April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiat...

2 months ago - PRNewsWire

I-Mab Announces Closing of the Divestiture of Business Operations in China

ROCKVILLE, Md. , April 2, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of high...

2 months ago - PRNewsWire

I-Mab Reports Full Year 2023 Financial Results and Business Update

Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to close by the end of March 2024 Uliledlimab (...

3 months ago - PRNewsWire

Biotech firm I-Mab to divest China operations, shift focus to US

I-Mab said on Wednesday it has agreed to divest its operations and assets in China as part of its strategy to become a U.S.-focused biotech firm, sending the company's shares up nearly 11% in premarke...

4 months ago - Reuters

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

Agreement marks an important milestone to advance the Company's intent to become a U.S.-based biotech  Agreement provides for a strategic focus in advancing I-Mab's potential of differentiated oncolog...

4 months ago - PRNewsWire

I-Mab Announces Participation at Jefferies and Piper Conferences in November

ROCKVILLE, Md. and SHANGHAI, China , Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients a...

7 months ago - PRNewsWire

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

FDA granted Breakthrough Therapy Designation for felzartamab in PMN upon positive clinical data from M-PLACE, a Phase 2 study led by I-Mab partner HI-Bio I-Mab has full development and commercializati...

8 months ago - PRNewsWire

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

ROCKVILLE, MD, U.S. and SHANGHAI, China , Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patie...

8 months ago - PRNewsWire

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

ROCKVILLE, Md. and SHANGHAI, China , Oct. 16, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients ...

8 months ago - PRNewsWire

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

-        Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete response, one had partial response and two unconfirmed partial responses; maximum tolerated dose not...

8 months ago - PRNewsWire

AbbVie terminates deal with I-Mab to develop cancer drug

China-based biotech company I-Mab said on Friday that AbbVie has terminated a 2020 deal to co-develop and market I-Mab's lead cancer drug candidate lemzoparlimab.

Other symbols: ABBV
9 months ago - Reuters

I-Mab Announces Upcoming Participation at September Conferences

ROCKVILLE, Md. and SHANGHAI , Sept.

10 months ago - PRNewsWire

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

Significant progress made year-to-date on key clinical assets:‐         Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023‐         Givastomig (Claudin 18.2 x 4-1BB bis...

10 months ago - PRNewsWire

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

ROCKVILLE, Md. and SHANGHAI , Aug. 8, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializati...

11 months ago - PRNewsWire

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

GAITHERSBURG, Md. and SHANGHAI , July 5, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializ...

1 year ago - PRNewsWire

I-Mab Announces the Appointment of Raj Kannan as CEO

GAITHERSBURG, Md. and SHANGHAI, June 22, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and c...

1 year ago - PRNewsWire

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

-  Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation of patients' immune system against cancer cells. -  In newly diagnosed patients who were ...

1 year ago - PRNewsWire

I-MAB Filed 2022 Annual Report on Form 20-F

GAITHERSBURG, Md. and SHANGHAI , May 1, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and co...

1 year ago - PRNewsWire

I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023

GAITHERSBURG, Md. and SHANGHAI , April 26, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercial...

1 year ago - PRNewsWire

I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon

Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute Tribunal completely denied Tracon's groundless damages claim of over $200 million re...

1 year ago - PRNewsWire

I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China

GAITHERSBURG, Md. and SHANGHAI , April 24, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercial...

1 year ago - PRNewsWire